Kreuter M, et al. - In the INPULSIS trials, it was inquired if statin use at baseline was associated with differences in disease progression in placebo-treated patients or impacted the treatment effect of nintedanib. Statin use at baseline resulted in a numerically lower forced vital capacity decline in placebo-treated patients with idiopathic pulmonary fibrosis, compared with those who did not receive statin at baseline. Furthermore, treatment effect of nintedanib was not impacted by use of statins at baseline.